EMA hesitates over flunking Curevac vaccine despite missed target

The European Medicines Agency is reluctant to implement the 50 percent efficacy threshold for covid-19 vaccines.

Photo: Yves Herman/REUTERS / X00380

On Thursday, the European Medicines Agency (EMA) reported that it will not be implementing a 50 percent efficacy threshold for covid-19 vaccines.

On Wednesday, it emerged that the Curevac vaccine has 47 percent efficacy. It therefore does not live up to statistical success criteria.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs